Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
NORTHBROOK, Ill., Nov. 3, 2014 /PRNewswire/ -- Astellas announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of...
SAN FRANCISCO, CA and NORTHBROOK, IL – October 30, 2014 – Medivation Inc. (NASDAQ: MDVN) and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the...
Company is Exclusive Healthcare Sponsor of USA Eagles vs. New Zealand All Blacks Rugby Match at Soldier Field on Nov. 1 NORTHBROOK, Ill., Oct. 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., in...
NORTHBROOK, Ill., Oct. 8, 2014 /PRNewswire/ -- Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3...
Read more about Astellas Presents New Findings For Isavuconazole In Mucormycosis At IDWeek
NORTHBROOK, Ill., Oct. 2, 2014 /PRNewswire/ -- Astellas, a pharmaceutical company based in Northbrook, Ill., launched a new benefits program today to provide support for its almost 3,000 US-based...
Follow U.S. news
